| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 04/14/2005 | WO2005033309A2 Plant promoters and methods of use thereof |
| 04/14/2005 | WO2005033308A1 Schizophrenia-associated protein and gene coding for the same |
| 04/14/2005 | WO2005033293A2 Hypoxia - responsive human cngh-0002 genes and polypeptides |
| 04/14/2005 | WO2005033284A2 Compositions and methods for gene expression |
| 04/14/2005 | WO2005033281A2 A process of making transgenic mammals that produce exogenous proteins in milk and transgenic mammals produced thereby |
| 04/14/2005 | WO2005033274A2 A process for producing exogenous protein in the milk of trangenic mammals and a process for purifying proteins therefrom |
| 04/14/2005 | WO2005033270A2 Vectors and transfected cells |
| 04/14/2005 | WO2005033267A2 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| 04/14/2005 | WO2005033266A2 Regulation of acheron expression |
| 04/14/2005 | WO2005033265A2 Optimized multi-epitope constructs and uses thereof |
| 04/14/2005 | WO2005033144A2 Tim-3 polypeptides |
| 04/14/2005 | WO2005033141A1 Regulation of matrix metalloproteinases by psp94 family members |
| 04/14/2005 | WO2005033139A2 Novel calcium channels and uses thereof |
| 04/14/2005 | WO2005033138A1 Altering the concentration of intracellular agents by p2x7 receptor modulation |
| 04/14/2005 | WO2005033137A1 Modified ciliary neurotrophic factor polypeptides with reduced antigenicity |
| 04/14/2005 | WO2005033136A1 Unique integrin binding site in connective tissue growth factor (ctgf) |
| 04/14/2005 | WO2005033135A1 Process for purifying human thrombopoietin with high content of sialic acid |
| 04/14/2005 | WO2005033134A2 Secreted protein therapeutics and uses thereof |
| 04/14/2005 | WO2005033133A2 Polynucleotides encoding erbb-2 polypeptides and kits and methods using same |
| 04/14/2005 | WO2005033132A2 Igf binding proteins |
| 04/14/2005 | WO2005033131A1 Amyloid formation |
| 04/14/2005 | WO2005033130A2 Mutated ig binding domains of protein l |
| 04/14/2005 | WO2005033126A1 Cell surface marker |
| 04/14/2005 | WO2005033125A2 Mammalian t1r3 sweet taste receptors |
| 04/14/2005 | WO2005032586A1 Optimized expression of hpv 45 l1 in yeast |
| 04/14/2005 | WO2005032585A1 Pharmaceutical compositions containing human papilloma virus antigens |
| 04/14/2005 | WO2005032582A2 Immunogenic compositions for streptococcus pyogenes |
| 04/14/2005 | WO2005032575A1 Protein kinase c peptides for use in withdrawal |
| 04/14/2005 | WO2005032561A1 INVENTION RELATING TO FUNCTION OF HIV-Vpr |
| 04/14/2005 | WO2005032487A2 Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus |
| 04/14/2005 | WO2005032482A2 Treatment of demyelinating autoimmune disease with modified ordered peptides |
| 04/14/2005 | WO2005032476A2 Methods and compositions for cpg15-2 |
| 04/14/2005 | WO2005032469A2 METHODS FOR REGULATING BUD-HYPHA TRANSITION AND cAMP LEVELS IN CANDIDA ALBICANS |
| 04/14/2005 | WO2005032460A2 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 04/14/2005 | WO2005032454A2 Anti-muc-1 single chain antibodies for tumor targeting |
| 04/14/2005 | WO2005032453A2 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/14/2005 | WO2005032399A2 Il4 receptor antagonists for horse, dog and cat |
| 04/14/2005 | WO2005032245A1 Method of producing transgenic pigs expressing green fluorescent protein |
| 04/14/2005 | WO2005032244A1 Transgenic animals with serious disorders related to alzheimer's disease |
| 04/14/2005 | WO2005018663A8 G-csf derivative for inducing immunological tolerance |
| 04/14/2005 | WO2005017170A3 Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same |
| 04/14/2005 | WO2005005480A3 Taste receptors of the t1r family from domestic cat |
| 04/14/2005 | WO2005003315A3 Compositions and methods for peptide-assisted transfection |
| 04/14/2005 | WO2004113546A3 CASTANEA SATIVA MILL. GENES CODIFYING FOR ALLENE OXIDE CYCLASE, CYSTATIN, β-1,3-GLUCANASE AND THAUMATIN-LIKE PROTEIN AND THEIR USE |
| 04/14/2005 | WO2004112706A3 Vaccines, immunotherapeutics and methods for using the same |
| 04/14/2005 | WO2004104039A8 Tumor antigens for prevention and/or treatment of cancer |
| 04/14/2005 | WO2004101739A3 Methods for chemically synthesizing immunoglobulin chimeric proteins |
| 04/14/2005 | WO2004096990A3 Pathophysiology associated with a single gene (mass1) mutation underlying the robust audiogenic seizure phenotype in frings mice |
| 04/14/2005 | WO2004093892A3 Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization |
| 04/14/2005 | WO2004092215A3 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |
| 04/14/2005 | WO2004092212A3 Tumor antigens bfa5 for prevention and/or treatment of cancer |
| 04/14/2005 | WO2004067564B1 Compositions against cancer antigen liv-1 and uses thereof |
| 04/14/2005 | WO2004062574A3 Improved linkers for radiopharmaceutical compounds |
| 04/14/2005 | WO2004047767A3 Methods for identifying risk of breast cancer and treatments thereof |
| 04/14/2005 | WO2004046168A3 Recombinant hiv-1 subclass d envelope glycoproteins |
| 04/14/2005 | WO2004039955A3 Modulators of angiogenesis and tumorigenesis |
| 04/14/2005 | WO2004039307A3 Methods and compositions for diagnosing and treating companion animal cancer |
| 04/14/2005 | WO2004037984A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 04/14/2005 | WO2004037205A8 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
| 04/14/2005 | WO2004031105A3 Use of a33 antigens and jam-it |
| 04/14/2005 | WO2004027036A3 Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| 04/14/2005 | WO2004026228A3 Method for reducing morbidity and mortality in critically ill patients |
| 04/14/2005 | WO2004024069A3 Novel compositions and methods for the treatment of immune-related diseases |
| 04/14/2005 | WO2004016739A3 Cell modulation using a cytoskeletal protein |
| 04/14/2005 | WO2004013609A3 Use of biomarkers for detecting ovarian cancer |
| 04/14/2005 | WO2004013347A3 Methods of identifying compounds that modulate protein activity |
| 04/14/2005 | WO2004011485A3 Stabilized bioactive peptides and methods of identification, synthesis, and use |
| 04/14/2005 | WO2004007687A3 Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers |
| 04/14/2005 | WO2003091277A3 Haplotypes of the cetp gene |
| 04/14/2005 | WO2003086453A9 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
| 04/14/2005 | WO2003074672A3 Crebpas as modifiers of cell death pathways and methods of use |
| 04/14/2005 | WO2003053339A3 Insulin molecule having protracted time action |
| 04/14/2005 | WO2003040340A3 Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| 04/14/2005 | WO2003040322A3 Promoters for regulation of gene expression in plant roots |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | WO2003015712A3 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 04/14/2005 | WO2002079417A3 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 04/14/2005 | US20050081265 Maize chloroplast protein synthesis elongation factors and methods of use for same |
| 04/14/2005 | US20050081262 The DMI1 gene encodes a protein that is required for the early steps of bacterial and fungal symbioses |
| 04/14/2005 | US20050081256 Transgenic mammal comprising regulatory sequences which permit for preferential selection of sex chromosome in mammalian offspring; sex determination; tissue engineering |
| 04/14/2005 | US20050080250 Methods of stimulating growth of stromal cells in a human |
| 04/14/2005 | US20050080247 Leinamycin biosynthesis gene cluster and its components and their uses |
| 04/14/2005 | US20050080243 Screening for enzyme inhibitors; signal transduction passageways' chelation enhancement fluorescence |
| 04/14/2005 | US20050080242 Fluorescence assay for kinase activity |
| 04/14/2005 | US20050080241 Human hepatoma-derived growth factor 5, its encoding sequence, method for producing it and the uses of it |
| 04/14/2005 | US20050080237 Oligomeric molecules and uses thereof |
| 04/14/2005 | US20050080236 Virus suppressing factor (VSF) for use in treatment and prevention of viral infection in animal and humans |
| 04/14/2005 | US20050080235 Ret ligand (RetL) for stimulating neural and renal growth |
| 04/14/2005 | US20050080234 Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| 04/14/2005 | US20050080233 Expression vector comprising nucleotide sequences coding bacterial outer membrane protein for use in diagnosis, prevention and treatment of microorganismal infection |
| 04/14/2005 | US20050080232 Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| 04/14/2005 | US20050080231 Small peptides having apoptotic activities and their applications |
| 04/14/2005 | US20050080133 Methods of inhibiting osteoclast activity |
| 04/14/2005 | US20050080054 selective androgen receptor modulator (SARM); sexual dysfunction hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity |
| 04/14/2005 | US20050080027 Methods enabling the production yield of viral vectors derived from piroviruses to be improved by using DNA methylation inhibitors and/or Herpes viruses in the production of viral vectors derived from parvoviruses; suitable for transferring genes into mammalian cells, in particular into human cells |
| 04/14/2005 | US20050080015 Carboline-3-carboxylic acid modified related sequences of Ala-Arg-Pro-Ala-Lys, their synthesis and use as thromobolytic agent |
| 04/14/2005 | US20050080014 Thrombopoietic compounds |
| 04/14/2005 | US20050080013 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; multimeric Apo-A-1agonist; anticholesterol agents; hypercholesterolemia, septic shock |
| 04/14/2005 | US20050080008 Administering bactericidal permeability increasing protein products; anticoagulants; without severe adverse side effects |
| 04/14/2005 | US20050080001 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |